VYNE Therapeutics Inc. Common Stock (VYNE) Stock Price

VYNEStock
$39.50+136.53%52W
Market Cap$26.37M
P/E
PEG Ratio
Div yield
Beta2.09

VYNE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)19.55%
Price vs S&P 500 (4W)37.77%
VGM Score42.68

VYNE Earnings Surprise History

Q1 25-10.00est. -14.50
Q2 25-6.50est. -11.17
Q3 25-8.50est. -6.50
Q4 25-5.50est. -11.50

VYNE Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.90
4.00
4.00
4.00

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
VYNEVYNE Therapeutics Inc. Common Stock
DCB$39.50
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About VYNE Therapeutics Inc. Common Stock

VYNE Therapeutics is a biopharmaceutical company developing therapies for immuno-inflammatory skin conditions. The company markets dermatology products AMZEEQ and ZILXI while advancing FMX114 as its lead pipeline candidate for atopic dermatitis treatment. VYNE also maintains pre-clinical programs targeting BET inhibitors for potential future applications.